



SPAFID CONNECT

Informazione Regolamentata n. 0957-64-2019	Data/Ora Ricezione 27 Novembre 2019 07:58:38	MTA
--	--	-----

Societa' : DiaSorin

Identificativo : 125183

Informazione
Regolamentata

Nome utilizzatore : DIASORINN02 - Fava

Tipologia : REGEM

Data/Ora Ricezione : 27 Novembre 2019 07:58:38

Data/Ora Inizio : 27 Novembre 2019 07:58:39

Diffusione presunta

Oggetto : DIASORIN LAUNCHES THE LIAISON
QUANTIFERON-TB GOLD PLUS ASSAY
IN PARTNERSHIP WITH QIAGEN IN THE
US MARKET

Testo del comunicato

Vedi allegato.



DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET

November 27, 2019 - Saluggia, Italy and Hilden, Germany; **DiaSorin** (FTSE MIB: DIA) and **QIAGEN** (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of LIAISON QuantiFERON-TB Gold Plus (QFT-Plus), the automated fourth-generation modern gold standard for latent tuberculosis infection (LTBI) detection, on DiaSorin's LIAISON platforms.

The U.S. Food and Drug Administration (FDA) approved the LIAISON QuantiFERON-TB Gold Plus Test, developed by QIAGEN and DiaSorin to offer streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology. The highly automated workflow on LIAISON platforms provides QuantiFERON customers a powerful, highly flexible automation option for all throughput ranges.

LTBI is today a major healthcare problem with around one third of worldwide population carrying the infection, and with about 5-10% of this number progressing to active tuberculosis (TB) if untreated¹, thus causing around 1.7 million deaths every year and making it one of the top 10 causes of death worldwide.

Tuberculosis is a contagious bacterial infection spread primarily through coughing by patients with the active pulmonary form of the disease. In LTBI, the bacterium infects a person but produces no symptoms unless it progresses to active disease, at which stage the patient is highly contagious. As part of comprehensive programs to eradicate TB, WHO and other international organizations have expanded their guidelines for screening high-risk individuals and treating those with latent infection to help prevent further contagion and reduce the disease burden.

DiaSorin and QIAGEN will cooperate closely on the promotion and sales of the complete solution to latent TB testing to assure their customers to get the full benefits out of this collaboration.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented, *“Today we made a step further in our strategy to drive the conversion to the most advanced solution available in the market for the detection of latent tuberculosis. LIAISON QuantiFERON-TB Gold Plus Test, already available in Europe since September 2018, is now available in the United States on the LIAISON family platforms and we believe this solution for laboratories will furtherly strengthen our positioning as a specialty player”*.

“We are pleased to announce FDA approval of the LIAISON QuantiFERON-TB Gold Plus Test for use on the LIAISON platforms and the broad-based initiation of our launch for this new automation option in the United States. The validation of the QuantiFERON technology with the LIAISON platforms further reinforced the clinical profile of QuantiFERON-TB Gold Plus,” said **Thierry Bernard, Interim CEO of QIAGEN and Senior Vice President, Head of the Molecular Diagnostics Business Area**. *“Combined with front-end automation options for liquid handling, the LIAISON workflow for QFT-Plus delivers significant gains in turnaround time and efficiency”*.

¹ World Health Organization (WHO) estimates



About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 24 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin as the “Diagnostic Specialist”. Further information at <http://www.diasoringroup.com>.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma, R&D and industrial applications, primarily forensics). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at <http://www.qiagen.com>

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

For additional information, please contact:

DiaSorin

Riccardo Fava +39.0161.487988
Corporate VP Communication & Investor Relations
riccardo.fava@diasorin.it

QIAGEN

Investor Relations

John Gilardi +49.2103.29.11711
Phoebe Loh +49.2103.29.11457
ir@QIAGEN.com

Public Relations

Thomas Theuringer +49.2103.29.11826
Robert Reitze +49.2103.29.11676
pr@QIAGEN.com

Fine Comunicato n.0957-64

Numero di Pagine: 4